Drug intelligence / Profile preview

U101

Development stage: Unknown
Lead developer: TCM Biotech
Administration: Oral

Overview

U101 is a novel, non-antibiotic oral drug developed by TCM Biotech International Corp. for the treatment and prevention of recurrent urinary tract infections (rUTI). Its mechanism of action involves creating a protective barrier on the inner wall of the urinary tract, which prevents pathogenic bacteria from adhering to urothelial cells. Additionally, it facilitates the repair of damaged urothelial tissue, thereby effectively preventing recurrent infections. This drug is being developed as an innovative alternative to traditional antibiotic therapies and hyaluronic acid instillations for rUTI.

Beyond the preview

Go deeper on U101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on U101.

Explore the full profile